261 related articles for article (PubMed ID: 25284324)
1. Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.
Bradbury AM; Gray-Edwards HL; Shirley JL; McCurdy VJ; Colaco AN; Randle AN; Christopherson PW; Bird AC; Johnson AK; Wilson DU; Hudson JA; De Pompa NL; Sorjonen DC; Brunson BL; Jeyakumar M; Platt FM; Baker HJ; Cox NR; Sena-Esteves M; Martin DR
Exp Neurol; 2015 Jan; 263():102-12. PubMed ID: 25284324
[TBL] [Abstract][Full Text] [Related]
2. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system.
Rockwell HE; McCurdy VJ; Eaton SC; Wilson DU; Johnson AK; Randle AN; Bradbury AM; Gray-Edwards HL; Baker HJ; Hudson JA; Cox NR; Sena-Esteves M; Seyfried TN; Martin DR
ASN Neuro; 2015; 7(2):. PubMed ID: 25873306
[TBL] [Abstract][Full Text] [Related]
3. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
Lahey HG; Webber CJ; Golebiowski D; Izzo CM; Horn E; Taghian T; Rodriguez P; Batista AR; Ellis LE; Hwang M; Martin DR; Gray-Edwards H; Sena-Esteves M
Mol Ther; 2020 Oct; 28(10):2150-2160. PubMed ID: 32592687
[TBL] [Abstract][Full Text] [Related]
4. Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.
Golebiowski D; van der Bom IMJ; Kwon CS; Miller AD; Petrosky K; Bradbury AM; Maitland S; Kühn AL; Bishop N; Curran E; Silva N; GuhaSarkar D; Westmoreland SV; Martin DR; Gounis MJ; Asaad WF; Sena-Esteves M
Hum Gene Ther; 2017 Jun; 28(6):510-522. PubMed ID: 28132521
[TBL] [Abstract][Full Text] [Related]
5. Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.
McCurdy VJ; Rockwell HE; Arthur JR; Bradbury AM; Johnson AK; Randle AN; Brunson BL; Hwang M; Gray-Edwards HL; Morrison NE; Johnson JA; Baker HJ; Cox NR; Seyfried TN; Sena-Esteves M; Martin DR
Gene Ther; 2015 Feb; 22(2):181-9. PubMed ID: 25474439
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease.
McCurdy VJ; Johnson AK; Gray-Edwards HL; Randle AN; Bradbury AM; Morrison NE; Hwang M; Baker HJ; Cox NR; Sena-Esteves M; Martin DR
Gene Ther; 2021 Apr; 28(3-4):142-154. PubMed ID: 32884151
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.
Bradbury AM; Cochran JN; McCurdy VJ; Johnson AK; Brunson BL; Gray-Edwards H; Leroy SG; Hwang M; Randle AN; Jackson LS; Morrison NE; Baek RC; Seyfried TN; Cheng SH; Cox NR; Baker HJ; Cachón-González MB; Cox TM; Sena-Esteves M; Martin DR
Mol Ther; 2013 Jul; 21(7):1306-15. PubMed ID: 23689599
[TBL] [Abstract][Full Text] [Related]
8. AAV-mediated gene delivery attenuates neuroinflammation in feline Sandhoff disease.
Bradbury AM; Peterson TA; Gross AL; Wells SZ; McCurdy VJ; Wolfe KG; Dennis JC; Brunson BL; Gray-Edwards H; Randle AN; Johnson AK; Morrison EE; Cox NR; Baker HJ; Sena-Esteves M; Martin DR
Neuroscience; 2017 Jan; 340():117-125. PubMed ID: 27793778
[TBL] [Abstract][Full Text] [Related]
9. Life-Limiting Peripheral Organ Dysfunction in Feline Sandhoff Disease Emerges after Effective CNS Gene Therapy.
Johnson AK; McCurdy VJ; Gray-Edwards HL; Maguire AS; Cochran JN; Gross AL; Skinner HE; Randle AN; Shirley JL; Brunson BL; Bradbury AM; Leroy SG; Hwang M; Rockwell HE; Cox NR; Baker HJ; Seyfried TN; Sena-Esteves M; Martin DR
Ann Neurol; 2023 Nov; 94(5):969-986. PubMed ID: 37526361
[TBL] [Abstract][Full Text] [Related]
10. Reversibility of neuropathology in Tay-Sachs-related diseases.
Cachón-González MB; Wang SZ; Ziegler R; Cheng SH; Cox TM
Hum Mol Genet; 2014 Feb; 23(3):730-48. PubMed ID: 24057669
[TBL] [Abstract][Full Text] [Related]
11. Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy.
Gray-Edwards HL; Brunson BL; Holland M; Hespel AM; Bradbury AM; McCurdy VJ; Beadlescomb PM; Randle AN; Salibi N; Denney TS; Beyers RJ; Johnson AK; Voyles ML; Montgomery RD; Wilson DU; Hudson JA; Cox NR; Baker HJ; Sena-Esteves M; Martin DR
Mol Genet Metab; 2015; 116(1-2):80-7. PubMed ID: 25971245
[TBL] [Abstract][Full Text] [Related]
12. Treatment of GM2 Gangliosidosis in Adult Sandhoff Mice Using an Intravenous Self-Complementary Hexosaminidase Vector.
Osmon KJ; Thompson P; Woodley E; Karumuthil-Melethil S; Heindel C; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS
Curr Gene Ther; 2022; 22(3):262-276. PubMed ID: 34530708
[TBL] [Abstract][Full Text] [Related]
13. Genetics and Therapies for GM2 Gangliosidosis.
Cachon-Gonzalez MB; Zaccariotto E; Cox TM
Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
[TBL] [Abstract][Full Text] [Related]
14. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
Huang JQ; Trasler JM; Igdoura S; Michaud J; Hanal N; Gravel RA
Hum Mol Genet; 1997 Oct; 6(11):1879-85. PubMed ID: 9302266
[TBL] [Abstract][Full Text] [Related]
16. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
[TBL] [Abstract][Full Text] [Related]
17. Brain endothelial specific gene therapy improves experimental Sandhoff disease.
Dogbevia G; Grasshoff H; Othman A; Penno A; Schwaninger M
J Cereb Blood Flow Metab; 2020 Jun; 40(6):1338-1350. PubMed ID: 31357902
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus transformed lymphoid cell lines as a new model system in culture for the study of GM2-gangliosidoses: Tay-Sachs and Sandhoff diseases.
Maret A; Salvayre R; Negre A; Bes JC; Douste-Blazy L
Biol Cell; 1985; 53(3):293-6. PubMed ID: 2990625
[TBL] [Abstract][Full Text] [Related]
19. Biology and potential strategies for the treatment of GM2 gangliosidoses.
Chavany C; Jendoubi M
Mol Med Today; 1998 Apr; 4(4):158-65. PubMed ID: 9572057
[TBL] [Abstract][Full Text] [Related]
20. Characterization of inducible models of Tay-Sachs and related disease.
Sargeant TJ; Drage DJ; Wang S; Apostolakis AA; Cox TM; Cachón-González MB
PLoS Genet; 2012 Sep; 8(9):e1002943. PubMed ID: 23028353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
